alexa Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013 LOGiC--A Randomized Phase III Trial.
Gastroenterology

Gastroenterology

Journal of Gastrointestinal & Digestive System

Author(s): Hecht JR, Bang YJ, Qin SK, Chung HC, Xu JM,

Abstract Share this page

Abstract PURPOSE: To evaluate the efficacy of adding lapatinib to capecitabine and oxaliplatin (CapeOx) in patients with previously untreated human epidermal growth factor receptor 2 (HER2) -amplified advanced gastroesophageal adenocarcinoma. PATIENTS AND METHODS: Patients with HER2-positive advanced gastroesophageal adenocarcinoma were randomly assigned at a one-to-one ratio to CapeOx plus lapatinib 1,250 mg or placebo daily. Primary end point was overall survival (OS) in patients with centrally confirmed HER2 amplification in the primary efficacy population. RESULTS: A total of 545 patients were randomly assigned, and 487 patients comprised the primary efficacy population. Median OS in the lapatinib and placebo arms was 12.2 (95\% CI, 10.6 to 14.2) and 10.5 months (95\% CI, 9.0 to 11.3), respectively, which was not significantly different (hazard ratio, 0.91; 95\% CI, 0.73 to 1.12). Median progression-free survival in the lapatinib and placebo arms was 6.0 (95\% CI, 5.6 to 7.0) and 5.4 months (95\% CI, 4.4 to 5.7), respectively (hazard ratio, 0.82; 95\% CI, 0.68 to 1.00; P = .0381). Response rate was significantly higher in the lapatinib arm: 53\% (95\% CI, 46.4 to 58.8) compared with 39\% (95\% CI, 32.9 to 45.3) in the placebo arm (P = .0031). Preplanned exploratory subgroup analyses showed OS in the lapatinib arm was prolonged in Asian and younger patients. No correlation was observed between HER2 immunohistochemistry status and survival. There were increased toxicities in the lapatinib arm, particularly diarrhea. CONCLUSION: Addition of lapatinib to CapeOx did not increase OS in patients with HER2-amplified gastroesophageal adenocarcinoma. There were clear differences in the effect of lapatinib depending on region and age. Future studies could examine this correlation. TRIAL REGISTRATION: ClinicalTrials.gov NCT00680901. © 2015 by American Society of Clinical Oncology. This article was published in J Clin Oncol and referenced in Journal of Gastrointestinal & Digestive System

Relevant Expert PPTs

Recommended Conferences

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords